FMRI in analgesic drug discovery

Science Translational Medicine

Volumn 7, Issue 274, 2015, Pages

  Wager, Tor D ^a   Woo, Choong Wan ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; GABAPENTIN; MORPHINE; NAPROXEN; PREGABALIN; REMIFENTANIL; TETRAHYDROCANNABINOL; TRAMADOL;

AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; BRAIN FUNCTION; CHRONIC PAIN; DRUG DEVELOPMENT; DRUG EFFECT; DRUG MECHANISM; DRUG REPOSITIONING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; LATERAL PREFRONTAL CORTEX; NEUROIMAGING; NEUROPATHIC PAIN; NOCICEPTION; ORBITAL CORTEX; PARAHIPPOCAMPAL GYRUS; PREDICTION; PRIORITY JOURNAL; REVIEW; SUPPORT VECTOR MACHINE; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; NUCLEAR MAGNETIC RESONANCE IMAGING;

CENTRAL NERVOUS SYSTEM; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84929493748     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010342     Document Type: Review

References (10)

1. S. Kapur, A. G. Phillips, T. R. Insel, Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol. Psychiatry 17, 1174-1179 (2012).
2. D. Borsook, L. Becerra, R. Hargreaves, Biomarkers for chronic pain and analgesia. Part 2: How, where, and what to look for using functional imaging. Discov. Med. 11, 209-219 (2011).
3. M. Roy, D. Shohamy, T. D. Wager, Ventromedial prefrontal- subcortical systems and the generation of aff ective meaning. Trends Cogn. Sci. 16, 147-156 (2012).
4. D. T. Hsu, B. J. Sanford, K. K. Meyers, T. M. Love, K. E. Hazlett, H. Wang, L. Ni, S. J. Walker, B. J. Mickey, S. T. Korycinski, R. A. Koeppe, J. K. Crocker, S. A. Langenecker, J. K. Zubieta, Response of the μ-opioid system to social rejection and acceptance. Mol. Psychiatry 18, 1211-1217 (2013).
5. T. D. Wager, D. J. Scott, J. K. Zubieta, Placebo eff ects on human μ-opioid activity during pain. Proc. Natl. Acad. Sci. U.S.A. 104, 11056-11061 (2007).
6. E. P. Duff , W. Vennart, R. Wise, M. A. Howard, R. E. Harris, M. Lee, K. Wartolowska, V. Wanigasekera, F. J. Wilson, M. Whitlock, I. Tracey, M. W. Woolrich, S. M. Smith, Learning to identify CNS drug action and effi cacy using multistudy fMRI data. Sci. Transl. Med. 7, 274ra16 (2015).
7. S. Kam-Hansen, M. Jakubowski, J. M. Kelley, I. Kirsch, D. C. Hoaglin, T. J. Kaptchuk, R. Burstein, Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci. Transl. Med. 6, 218ra5 (2014).
8. L. Y. Atlas, R. A. Whittington, M. A. Lindquist, J. Wielgosz, N. Sonty, T. D. Wager, Dissociable infl uences of opiates and expectations on pain. J. Neurosci. 32, 8053-8064 (2012).
9. R. G. Wise, P. Williams, I. Tracey, Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacology 29, 626-635 (2004).
10. T. D. Wager, L. Y. Atlas, M. A. Lindquist, M. Roy, C. W. Woo, E. Kross, An fMRI-based neurologic signature of physical pain. N. Engl. J. Med. 368, 1388-1397 (2013).